Physician profile
Michael Sweeney
NPI 1124088141
$3,613.87
in general payments reported to CMS, 2019-2025
27 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $458 · 2021: $531 · 2022: $236 · 2023: $566 · 2024: $821 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $657.09 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $580.54 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $353.62 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $281.35 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $189.55 | 2019-2023 | Veozah |
| Merck Sharp & Dohme LLC | $173.31 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $152.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.73 | 2021-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $135.10 | 2019-2025 | Zoryve |
| Sanofi Pasteur INC. | $125.00 | 2019-2023 | |
| Pfizer INC. | $121.13 | 2019-2024 | |
| Exact Sciences Corporation | $114.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $114.28 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $97.54 | 2019-2021 | |
| Dexcom, INC. | $74.84 | 2024-2025 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $53.95 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $33.25 | 2023 | Rexulti |
| Abbvie INC. | $32.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.82 | 2021 | |
| Xeris Pharmaceuticals, INC. | $31.47 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $23.29 | 2023 | Proclaim |
| Genentech USA, INC. | $19.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.18 | 2022 | |
| Medtronic USA, INC. | $15.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.65 | 2022 | |
| Tactile Systems Technology INC | $15.43 | 2024 | Entre Plus, Flexitouch Plus |
| Sanofi-Aventis U.S. LLC | $14.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.